Having trouble accessing articles? Reset your cache.

Bifeprunox: Phase III data

In the double-blind, placebo-controlled Phase III ACNP 10214 trial in 497 patients, both 20 and 30 mg bifeprunox met the primary endpoint of time to deterioration

Read the full 261 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE